Previous Close | 4.95 |
Open | 4.92 |
Bid | 0.00 x 3000 |
Ask | 0.00 x 1400 |
Day's Range | 4.85 - 5.12 |
52 Week Range | 2.68 - 14.80 |
Volume | |
Avg. Volume | 1,262,127 |
Market Cap | 488.836M |
Beta (5Y Monthly) | 1.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.49 |
Earnings Date | Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for MRSN
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on August 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the second quarter ended June 30, 2022 on Monday, August 8, 2022 and will host a conference call and webcast at 4:30 p.m. Eastern Time t
Carla Poulson, Chief People Officer of Mersana Carla Poulson, Chief People Officer of Mersana, has been named as one of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America CAMBRIDGE, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that its S